The European Medicines Agency is set to make a crucial decision on whether Eli Lilly’s Alzheimer’s disease treatment, Kisunla (donanemab), will receive EU marketing approval. A positive outcome would be a significant milestone for the company in its fight against the devastating disease, which affects millions worldwide.
Source: https://insights.citeline.com/pink-sheet/product-reviews/eu-chmp/ema-poised-to-decide-on-fate-of-lillys-kisunla-and-pharmamars-aplidin-in-eu-BHN3A6PPD5HT3JHAPAV43VYYLU